Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 383-385

  Lundqvist, Andreas ^a   Berg, Maria ^b   Smith, Aleah ^b   Childs, Richard W ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Anti tumor immunity; Autologous natural killer cells; Bortezomib

Indexed keywords

BORTEZOMIB; INTERLEUKIN 2;

ADVANCED CANCER; ARTICLE; EX VIVO STUDY; HUMAN; NATURAL KILLER CELL; TUMOR IMMUNITY;

EID: 84861669615     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.383     Document Type: Article

References (10)

1. Srivastava S, Lundqvist A, Childs R. Natural Killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008;10:775-83.
2. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-3057.
3. Rubnitz JE IH, Ribeiro RC, Pounds S, et al. A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955-9.
4. Lundqvist A, McCoy JP, Samsel L, et al. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007;109:3603-6.
5. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
6. Lundqvist A, Abrams SI, Schrump DS, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006;66:7317-25.
7. Lundqvist A, Yokoyama H, Smith A, et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009;113:6120-7.
8. Lundqvist A, Su S, Rao S, et al. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J Immunol 2010;184:1139-42.
9. Lundqvist A, et al. Adoptive Infusion of Ex-Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity. Blood 2010; 114(1564):4080abs.
10. Berg M, Lundqvist A, McCoy P. Jr, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341-55.